ArticleCase reports in gastrointestinal medicine2018
Anti-PD-1 Therapy-Associated Perforating Colitis.
Article in Case reports in gastrointestinal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Guideline
- Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure.Journal of cancer research and clinical oncology · 2023Article
- Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.International journal of molecular sciences · 2023Review
- Article
- An updated review of gastrointestinal toxicity induced by PD-1 inhibitors: from mechanisms to management.Frontiers in immunology · 2023Review
- PD-L1, a Potential Immunomodulator Linking Immunology and Orthodontically Induced Inflammatory Root Resorption (OIIRR): Friend or Foe?International journal of molecular sciences · 2022Review
- Article
- RORγt Promotes Foxp3 Expression by Antagonizing the Effector Program in Colonic Regulatory T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Gas Bubbles: A Persistent Problem with Immunotherapy.Digestive diseases and sciences · 2021Article
- Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report.Annals of coloproctology · 2021Article
- Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.Current gastroenterology reports · 2020Review
- Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.Rheumatology (Oxford, England) · 2019Review
- Article
- Checkpoint inhibitors: What gastroenterologists need to know.World journal of gastroenterology · 2018Review
- Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhibition of immune checkpoint T cell regulatory molecules by using programmed cell death protein 1 (PD-1), or its ligand (PDL-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has been increasingly used to treat advanced malignancies. The immune-related adverse effects associated with these treatments such as diarrhea, colitis, and CTLA-4 treatment-associated perforating colitis have been reported. However, anti-PD-1/PD-L1-associated perforating colitis has rarely been reported. We report a case of colonic perforation in a patient recently treated with pembrolizumab, a PD-1 inhibitor for metastatic melanoma. Awareness of anti-PD-1/PD-L1-associated colitis and perforation will facilitate a timely diagnosis and management as they are increasingly used in oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.